XTX Topco Ltd Takes Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

XTX Topco Ltd bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,102 shares of the company's stock, valued at approximately $329,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Norges Bank acquired a new position in shares of Krystal Biotech in the 4th quarter worth approximately $34,391,000. Raymond James Financial Inc. purchased a new position in Krystal Biotech in the fourth quarter worth $15,989,000. Franklin Resources Inc. grew its position in shares of Krystal Biotech by 34.2% during the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company's stock valued at $43,774,000 after acquiring an additional 62,178 shares during the period. TimesSquare Capital Management LLC raised its position in shares of Krystal Biotech by 39.1% in the fourth quarter. TimesSquare Capital Management LLC now owns 158,868 shares of the company's stock valued at $24,888,000 after purchasing an additional 44,646 shares during the period. Finally, Vanguard Group Inc. grew its stake in Krystal Biotech by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock valued at $450,938,000 after acquiring an additional 28,707 shares in the last quarter. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Price Performance

Shares of KRYS traded down $1.66 during midday trading on Tuesday, reaching $168.07. The stock had a trading volume of 52,514 shares, compared to its average volume of 294,653. The company has a market capitalization of $4.86 billion, a P/E ratio of 55.77 and a beta of 0.75. Krystal Biotech, Inc. has a 52 week low of $141.72 and a 52 week high of $219.34. The firm's 50 day moving average price is $176.24 and its 200-day moving average price is $171.50.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.29 by $0.23. The business had revenue of $91.10 million for the quarter, compared to analysts' expectations of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. Krystal Biotech's quarterly revenue was up 116.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.30 earnings per share. On average, equities analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. HC Wainwright upped their price objective on shares of Krystal Biotech from $221.00 to $240.00 and gave the company a "buy" rating in a research note on Monday. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. Citigroup lifted their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a report on Thursday, February 20th. Chardan Capital upped their price objective on Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. Finally, Jefferies Financial Group started coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective for the company. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Krystal Biotech has an average rating of "Buy" and an average price target of $222.71.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares of the company's stock, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is owned by company insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).